PREVIA MEDICAL Company Profile

Background

Founded in 2020 and headquartered in Lyon, France, PREVIA MEDICAL specializes in developing artificial intelligence (AI)-driven predictive medical devices aimed at forecasting and preventing life-threatening emergencies in hospital settings. The company's mission is to enhance patient outcomes by enabling early detection of critical conditions, thereby allowing timely medical interventions. PREVIA MEDICAL's flagship product, SEPSI-SCORE, exemplifies this mission by providing early alerts for sepsis, a leading cause of hospital mortality worldwide.

Key Strategic Focus

PREVIA MEDICAL's strategic focus centers on integrating advanced AI technologies with existing hospital systems to provide real-time analysis of patient data. By leveraging digital biomarkers, the company aims to identify patients at risk of developing severe conditions such as sepsis, acute kidney injury (AKI), acute respiratory distress syndrome (ARDS), and cardiac arrest. The primary objective is to reduce inpatient length of stays and mortality rates by facilitating early detection and intervention.

Financials and Funding

In February 2023, PREVIA MEDICAL secured €2.1 million in seed funding. This round saw participation from investors including Kreaxi, M2care, Veymont Participations, Hopla Memory, CCI Capital Croissance, Holding Seraip, Bpifrance, and BNP Paribas. The capital is earmarked for conducting a prospective multicenter clinical trial for SEPSI-SCORE, with goals to scientifically validate the solution, reduce inpatient length of stays, and decrease sepsis-related mortality rates. Additionally, the funds will support team expansion and preparation for the commercial launch phase.

Pipeline Development

PREVIA MEDICAL's product pipeline includes:

• SEPSI-SCORE: Certified as a medical device in 2021, this AI-based solution analyzes real-time patient data to predict sepsis up to 48 hours before the onset of symptoms. Clinical trials are underway to validate its efficacy in reducing hospital stays and mortality rates.

• AKI Score: A digital biomarker under development aimed at early detection of acute kidney injury, a condition affecting millions annually. In October 2024, the project received a €1.1 million grant to fund research and development efforts.

• ARDS Score: In the project phase, this tool focuses on predicting acute respiratory distress syndrome, characterized by severe lung inflammation leading to breathing difficulties.

• ACR Score: Also in the project phase, this digital biomarker aims to detect risks of cardiac arrest, a sudden medical emergency causing loss of consciousness and breathing.

Technological Platform and Innovation

PREVIA MEDICAL's technological platform is distinguished by its:

• Proprietary AI Algorithms: Utilizing advanced machine learning techniques, the platform analyzes vast amounts of patient data to identify subtle patterns indicative of potential health deteriorations.

• Digital Biomarkers: The system employs digital biomarkers derived from real-time data, including vital signs, laboratory results, and medical history, to predict and prevent life-threatening emergencies.

• EHR Integration: Designed to be compatible with major Electronic Health Record (EHR) systems via FHIR technology, ensuring seamless integration and real-time data analysis.

Leadership Team

• Quentin François, CEO: An engineer with 15 years of experience in health information technologies, including a tenure on the executive committee of Cerner (Oracle Health). He has been instrumental in deploying EHR systems across renowned hospitals in Europe.

• Barthélémy Arribe, CTO: An engineer from the University of Technology of Compiègne with a decade of experience in application development, including roles as a FullStack developer in digital startups and as a freelancer. He co-founded PREVIA MEDICAL in 2020 and oversees all technical projects and infrastructure.

• Cécile Faure, Director of Clinical Research: Holding a doctorate from AgroParisTech, she has extensive experience managing large-scale international clinical research projects. Since 2024, she has led clinical research at PREVIA MEDICAL, ensuring scientific and clinical validation of medical devices.

• Axel Joron, Senior Software Engineer: With over 15 years in IT consulting and web application development, Axel joined PREVIA MEDICAL in 2023, contributing to all aspects of software development from design to maintenance.

• Sabrina Younsi, Partnerships & Marketing Manager: After 15 years in health benefits management and a business school specialization in health, she plays a crucial role in commercializing PREVIA MEDICAL's solutions and optimizing business growth.

• Alexia Idrac, Regulatory and Quality Affairs Officer: A final-year student at Polytech Grenoble in Health Information Technologies, she combines her medical technology education with regulatory and quality affairs responsibilities at PREVIA MEDICAL.

• Lionel Manzetti, Software Designer and Engineer: With a background in international business development and coworking space management, Lionel transitioned to software development, contributing his design and development skills to the team.

• Pierre-Elliott Thiboud, Data Scientist: A graduate of Polytech Lyon with a master's in Artificial Intelligence.